Signal transduction pathways: Targets for chemoprevention of skin cancer

Lancet Oncology

Volumn 1, Issue 3, 2000, Pages 181-188

  Bode, Ann M ^a   Dong, Zigang ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ISOTHIOCYANIC ACID DERIVATIVE; NONSTEROID ANTIINFLAMMATORY AGENT; PHYTIC ACID; RESVERATROL; STILBENE DERIVATIVE; TRANSCRIPTION FACTOR AP 1;

ANIMAL; CELL TRANSFORMATION; DISEASE MODEL; DRUG EFFECT; HUMAN; PATHOLOGY; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION; SKIN TUMOR; TEA;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICARCINOGENIC AGENTS; ASPIRIN; CELL TRANSFORMATION, NEOPLASTIC; DISEASE MODELS, ANIMAL; HUMANS; ISOTHIOCYANATES; NF-KAPPA B; PHYTIC ACID; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; STILBENES; TEA; TRANSCRIPTION FACTOR AP-1;

EID: 0034334115     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(00)00029-2     Document Type: Review

References (62)

1. Sporn MB, Suh N. Chemoprevention of cancer. Carcinogenesis 2000; 21: 525-30.
2. Sporn MB. Carcinogenesis and cancer: different perspectives on the same disease. Cancer Res 1991; 51: 6215-18.
3. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study [see comments]. J Natl Cancer Inst 1998; 90: 1371-88.
4. Veronesi U, De Palo G, Marubini E, et al. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer [see comments]. J Natl Cancer Inst 1999; 91: 1847-56.
5. Albanes D, Heinonen OP, Huttunen JK, et al. Effects of alpha-tocopherol and beta-carotene supplements on cancer incidence in the Alpha-Tocopherol Beta-Carotene Cancer Prevention Study. Am J Clin Nutr 1995; 62: 1427S-30S.
6. Omenn GS, Goodman GE, Thornquist MD, et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996; 334: 1150-55.
7. Prevention of cancer in the next millennium: report of the Chemoprevention Working Group to the American Association for Cancer Research. Cancer Res 1999; 59: 4743-58.
8. Mukhtar H, Mercurio MG, Agarwal R. Murine skin carcinogenesis: relevance to humans. In: Mukhtar H, ed. Skin cancer: mechanisms and human relevance. Boca Raton: CRC Press, 1995; 441: 3-8
9. Leffell DJ. The scientific basis of skin cancer. J Am Acad Dermatol 2000; 42: 18-22.
10. Hansen LA, Sigman CC, Andreola F, Ross SA, Kelloff GJ, De Luca LM. Retinoids in chemoprevention and differentiation therapy. Carcinogenesis 2000; 21: 1271-79.
11. Agarwal R, Mukhtar H. Cutaneous chemical carcinogenesis. In: Mukhtar H, ed. Pharmacology of the skin. Boca Raton: CRC Press, 1992: 434.
12. DiGiovanni J. Multistage carcinogenesis in mouse skin. Pharmacol Ther 1992; 54: 63-128.
13. Huang C, Schmid PC, Ma WY, Schmid HH, Dong Z. Phosphatidylinositol-3 kinase is necessary for 12-O-tetradecanoylphorbol-13-acetate-induced cell transformation and activated protein 1 activation. J Biol Chem 1997; 272: 4187-94.
14. Angel P, Karin M. The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation. Biochim Biophys Acta 1991; 1072: 129-57.
15. Barthelman M, Chen W, Gensler HL, Huang C, Dong Z, Bowden GT. Inhibitory effects of perillyl alcohol on UVB-induced murine skin cancer and AP-1 transactivation. Cancer Res 1998; 58: 711-16.
16. Dong Z, Watts SG, Sun Y, Colburn NH. Progressive elevation of AP-1 activity during preneoplastic-to neoplastic progression as modeled in mouse JB6 cell variants. Int J Oncol 1995; 7: 359-64.
17. Dong Z, Birrer MJ, Watts RG, Matrisian LM, Colburn NH. Blocking of tumor promoter-induced AP-1 activity inhibits induced transformation in JB6 mouse epidermal cells. Proc Natl Acad Sci USA 1994; 91: 609-13.
18. Kallunki T, Su B, Tsigelny I, et al. JNK2 contains a specificity-determining region responsible for efficient c-Jun binding and phosphorylation. Genes Dev 1994; 8: 2996-3007.
19. Cowley S, Paterson H, Kemp P, Marshall CJ. Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell 1994; 77: 841-52.
20. Baldwin AS, Jr. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol 1996; 14: 649-83.
21. Schulze-Osthoff K, Ferrari D, Riehemann K, Wesselborg S. Regulation of NF-kappa B activation by MAP kinase cascades. Immunobiology 1997; 198: 35-49.
22. Gilmore TD. Clinically relevant findings. J Clin Invest 1997; 100: 2935-36.
23. Li JJ, Westergaard C, Ghosh P, Colburn NH. Inhibitors of both nuclear factor-κB and activator protein-1 activation block the neoplastic transformation response. Cancer Res 1997; 57: 3569-76.
24. Marks F, Furstenberger G. Cancer chemoprevention through interruption of multistage carcinogenesis. The lessons learned by comparing mouse skin carcinogenesis and human large bowel cancer. Eur J Cancer 2000; 36: 314-29.
25. Marks F, Furstenberger G, Muller-Decker K. Metabolic targets of cancer chemoprevention: interruption of tumor development by inhibitors of arachidonic acid metabolism. Recent Results Cancer Res 1999; 151: 45-67.
26. Guan Z, Buckman SY, Miller BW, Springer LD, Morrison AR. Interleukin-1beta-induced cyclooxygenase-2 expression requires activation of both c-Jun NH2-terminal kinase and p38 MAPK signal pathways in rat renal mesangial cells. J Biol Chem 1998; 273: 28670-76.
27. Dean JL, Brook M, Clark AR, Saklatvala J. p38 mitogen-activated protein kinase regulates cyclooxygenase-2 mRNA stability and transcription in lipopolysaccharide-treated human monocytes. J Biol Chem 1999; 274: 264-69.
28. Subbaramaiah K, Chung WJ, Dannenberg AJ. Ceramide regulates the transcription of cyclooxygenase-2. Evidence for involvement of extracellular signal-regulated kinase/c-Jun N-terminal kinase and p38 mitogen-activated protein kinase pathways. J Biol Chem 1998; 273: 32943-49.
29. Dong Z, Huang C, Brown RE, Ma WY. Inhibition of activator protein 1 activity and neoplastic transformation by aspirin. J Biol Chem 1997; 272: 9962-70.
30. Ding M, Dong Z, Chen F, et al. Asbestos induces activator protein-1 transactivation in transgenic mice. Cancer Res 1999; 59: 1884-89.
31. Suganuma M, Okabe S, Marino MW, Sakai A, Sueoka E, Fujiki H. Essential role of tumor necrosis factor alpha (TNF-alpha) in tumor promotion as revealed by TNF-alpha-deficient mice. Cancer Res 1999; 59: 4516-18.
32. Moore RJ, Owens DM, Stamp G, et al. Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis [correction Nat Med 1999; 5: 1087]. Nat Med 1999; 5: 828-31.
33. Schwenger P, Bellosta P, Vietor I, Basilico C, Skolnik EY, Vilcek J. Sodium salicylate induces apoptosis via p38 mitogen-activated protein kinase but inhibits tumor necrosis factor-induced c-Jun N-terminal kinase/stress-activated protein kinase activation. Proc Natl Acad Sci USA 1997; 94: 2869-73.
34. Schwenger P, Alpert D, Skolnik EY, Vilcek J. Activation of p38 mitogen-activated protein kinase by sodium salicylate leads to inhibition of tumor necrosis factor-induced IkappaB alpha phosphorylation and degradation. Mol Cell Biol 1998; 18: 78-84.
35. Schwenger P, Alpert D, Skolnik EY, Vilcek J. Cell-type-specific activation of c-Jun N-terminal kinase by salicylates. J Cell Physiol 1999; 179: 109-14.
36. Stevenson MA, Zhao MJ, Asea A, Coleman CN, Calderwood SK. Salicylic acid and aspirin inhibit the activity of RSK2 kinase and repress RSK2-dependent transcription of cyclic AMP response element binding protein- and NF-kappa B-responsive genes. J Immunol 1999; 163: 5608-16.
37. Huang C, Ma WY, Hanenberger D, Cleary MP, Bowden GT, Dong Z. Inhibition of ultraviolet B-induced activator protein-1 (AP-1) activity by aspirin in AP-1-luciferase transgenic mice. J Biol Chem 1997; 272: 26325-31.
38. Ma WY, Huang C, Dong Z. Inhibition of ultraviolet C irradiation-induced AP-1 activity by aspirin is through inhibition of JNKs but not ERKs or P38 MAP kinase. Int J Oncol 1998; 12: 565-68.
39. Trevisanato SI, Kim YI. Tea and health. Nutr Rev 2000; 58: 1-10.
40. Yang CS, Chung JY, Yang G, Chhabra SK, Lee MJ. Tea and tea polyphenols in cancer prevention. J Nutr 2000; 130 (2S suppl): 472S-78S.
41. Dong Z, Ma W, Huang C, Yang CS. Inhibition of tumor promoter-induced activator protein 1 activation and cell transformation by tea polyphenols, (-)-epigallocatechin gallate, and theaflavins. Cancer Res 1997; 57: 4414-19.
42. Chung JY, Huang C, Meng X, Dong Z, Yang CS. Inhibition of activator protein 1 activity and cell growth by purified green tea and black tea polyphenols in H-ras-transformed cells: structure-activity relationship and mechanisms involved. Cancer Res 1999; 59: 4610-17.
43. Katiyar SK, Challa A, McCormick TS, Cooper KD, Mukhtar H. Prevention of UVB-induced immunosuppression in mice by the green tea polyphenol (-)-epigallocatechin-3-gallate may be associated with alterations in IL-10 and IL-12 production. Carcinogenesis 1999; 20: 2117-24.
44. Nomura M, Ma WY, Huang C, et al. Inhibition of ultraviolet B-induced AP-1 activation by theaflavins from black tea. Mol Carcinog 2000; 28: 148-55.
45. Barthelman M, Bair WB III, Stickland KK, et al. (-)-Epigallocatechin-3-gallate inhibition of ultraviolet B-induced AP-1 activity. Carcinogenesis 1998; 19: 2201-04.
46. Chen W, Dong Z, Valcic S, Timmermann BN, Bowden GT. Inhibition of ultraviolet B-induced c-fos gene expression and p38 mitogen-activated protein kinase activation by (-)-epigallocatechin gallate in a human keratinocyte cell line. Mol Carcinog 1999; 24: 79-84.
47. Ahmad N, Gupta S, Mukhtar H. Green tea polyphenol epigallocatechin-3-gallate differentially modulates nuclear factor kappaB in cancer cells versus normal cells. Arch Biochem Biophys 2000; 376: 338-46.
48. Pan MH, Lin-Shiau SY, Ho CT, Lin JH, Lin JK. Suppression of lipopolysaccharide-induced nuclear factor-κB activity by theaflavin-3,3′-digallate from black tea and other polyphenols through down-regulation of IκB kinase activity in macrophages. Biochem Pharmacol 2000; 59: 357-67.
49. Jang M, Cai L, Udeani GO, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997; 275: 218-20.
50. Huang C, Ma WY, Goranson A, Dong Z. Resveratrol suppresses cell transformation and induces apoptosis through a p53-dependent pathway. Carcinogenesis 1999; 20: 237-42.
51. Bardeesy N, Beckwith JB, Pelletier J. Clonal expansion and attenuated apoptosis in Wilms' tumors are associated with p53 gene mutations. Cancer Res 1995; 55: 215-19.
52. Subbaramaiah K, Chung WJ, Michaluart P, et al. Resveratrol inhibits cyclooxygenase-2 transcription and activity in phorbol ester-treated human mammary epithelial cells. J Biol Chem 1998; 273: 21875-82.
53. Mutoh M, Takahashi M, Fukuda K, et al. Suppression of cyclooxygenase-2 promoter-dependent transcriptional activity in colon cancer cells by chemopreventive agents with a resorcin-type structure. Carcinogenesis 2000; 21: 959-63.
54. Garcia-Garcia J, Micol V, de Godos A, Gomez-Fernandez JC. The cancer chemopreventive agent resveratrol is incorporated into model membranes and inhibits protein kinase C alpha activity. Arch Biochem Biophys 1999; 372: 382-88.
55. Huang C, Ma WY, Li J, Hecht SS, Dong Z. Essential role of p53 in phenethyl isothiocyanate-induced apoptosis. Cancer Res 1998; 58: 4102-06.
56. Kong AN, Mandlekar S, Yu R, Lei W, Fasanmande A. Pharmacodynamics and toxicodynamics of drug action: signaling in cell survival and cell death. Pharm Res 1999; 16: 790-98.
57. Patten EJ, DeLong MJ. Temporal effects of the detoxification enzyme inducer, benzyl isothiocyanate: activation of c-Jun N-terminal kinase prior to the transcription factors AP-1 and NFκB. Biochem Biophys Res Commun 1999; 257: 149-55.
58. Chen YR, Wang W, Kong AN, Tan TH. Molecular mechanism of c-Jun N-terminal kinase-mediated apoptosis induced by anticarcinogenic isothiocyanates. J Biol Chem 1998; 273: 1769-75.
59. Shamsuddin AM, Vucenik I. Mammary tumor inhibition by IP6: a review. Anticancer Res 1999; 19: 3671-74.
60. Saied IT, Shamsuddin AM. Up-regulation of the tumor suppressor gene p53 and WAF1 gene expression by IP6 in HT-29 human colon carcinoma cell line. Anticancer Res 1998; 18: 1479-84.
61. Huang C, Ma WY, Hecht SS, Dong Z. Inositol hexaphosphate inhibits cell transformation and activator protein 1 activation by targeting phosphatidylinositol-3′ kinase [published erratum appears in Cancer Res 1997 Nov 15; 57(22): 5198]. Cancer Res 1997; 57: 2873-78.
62. Dong Z, Huang C, Ma WY. PI-3 kinase in signal transduction, cell transformation, and as a target for chemoprevention of cancer. Anticancer Res 1999; 19: 3743-77.